MedTrace Logo

Quinacrine Treatment in Patients With Androgen-Independent Prostate Cancer

NCT00417274 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 31

Last updated 2013-04-11

Study results available
· View outcomes & findings →

Summary

The purpose of this study is to determine whether quinacrine is effective in the treatment of Androgen-Independent Prostate Cancer.

Conditions

  • Prostatic Cancer

Interventions

DRUG

Quinacrine

100 mg daily

Sponsors & Collaborators

  • Cleveland BioLabs

    lead INDUSTRY

Principal Investigators

  • Edwin Posadas, MD · University of Chicago Hospitals

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
MALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2006-12-31
Primary Completion
2008-05-31
Completion
2008-05-31

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00417274 on ClinicalTrials.gov